Inpatient Hospices in Germany: Medical Care Situation and Use of Supportive Oncological Therapies for Symptom Control in Tumor Patients

Ulrich Kaiser, Ursula Vehling-Kaiser, MD, Ana Hoffmann, PhD, and Florian Kaiser, MD, PhD

Abstract

Background: More than 80% of the residents in German hospices suffer from tumor disease. But the administration of supportive-oncological therapies in hospices for symptom control is controversially discussed.

Objectives: This study aims to investigate the care situation of tumor patients in German hospices with regard to medical care and the use of supportive-oncological therapies.

Methods: In February 2019, all hospices in Germany were offered the opportunity to participate in an anonymous online survey on medical and drug care for their tumor patients. The survey was conducted using the online platform SoSci Survey and ended in April 2019. The analysis was descriptive.

Results: Of 202 hospices, 112 responded to the questionnaire. The hospices were distributed nationwide. Most have 8 to 10 places. More than 80% of hospice residents are tumor patients, and the length of stay is usually three to four weeks. Medical care is primarily provided by primary care physicians. While specialized outpatient palliative care is increasingly involved in care, hematologists/oncologists are rarely represented. Supportive-oncological therapies are rarely prescribed, whereas medication for other chronic conditions is often continued. The percentage of supportive-oncological therapies prescribed is higher in hospices with oncology co-care.

Conclusions: Although most hospice residents suffer from malignant disease, co-care by a hematologist/oncologist is rare. Supportive-oncology therapies, particularly for symptom relief, may therefore be rarely used. However, since a small select group of hospice residents may benefit from these therapies, further investigation in this direction should be undertaken.

Keywords: hematologist/oncologist; hospice; supportive-oncology therapy; symptom control; tumor patient
Introduction

In Germany, about 33,500 people with advanced and incurable diseases are currently treated in about 200 inpatient adult hospices yearly. A predominant number (>80%) of palliative-care patients in both inpatient and outpatient settings suffer from an underlying malignant disease. In 2016, Dasch et al demonstrated that with increasing implementation of inpatient hospices, the proportion of cancer patients who died in hospices also significantly increased. Current data confirm this trend. In cancer patients, particularly, complications occur at the end of their lives, which may require specific therapy to alleviate symptoms. These include pain (caused e.g., by osteolysis, meningeosis carcinomatosa/leukemia, or plexus infiltration), bleeding, ulcerating wounds, dyspnea, weakness caused by anemia, or neurological symptoms because of hypercalcemia.

The use of supportive oncological therapies (e.g., radiotherapy, antiproliferative therapies, bisphosphonates, or blood products) with the aim of symptom control and improvement of the quality of life can be a sensible approach here: particularly, the use of antiproliferative therapy in an intravenous, oral, or intrathecal form, the transfusion of blood products (erythrocyte concentrates and platelet concentrates) or the administration of human albumin and bisphosphonates have already been successfully used here in palliative patients. This situation is similar to radiotherapy, which can significantly benefit patients for symptom control in enhanced pain therapy or in the case of bleeding or ulcerating tumors.

However, their use in hospices is not self-evident, is handled differently, and is controversially discussed. While the integration of palliative medicine in tumor patients is increasingly occurring in the early stages of metastasis parallel to oncological therapies, there are often conflicting ideas about the use of supportive oncological tumor therapies at the end of life, i.e., also in hospices, even if these therapeutic measures are exclusively used to control symptoms. A survey conducted as part of the Hospice and Palliative Survey HOPE in 2007 showed that 6.4% of patients in outpatient and inpatient palliative-care facilities received tumor-specific therapy—except for inpatient hospices. No anticancer therapies were realized here.

Simultaneously, inpatient hospices' medical care and administration are not uniform but include different specialist groups (e.g., general practitioners, palliative medicine physicians, and oncologists); however, medical care and administration are already partly accepted in hospices. In addition, specific therapies, such as the administration of antiproliferative substances, blood transfusions, and radiotherapy, usually require the cooperation of an oncologist, radiotherapist, or palliative medicine physician with oncological experience.

In principle, it is officially permissible to use oncological therapies, for example, chemotherapy or radiotherapy, in German hospices if they serve exclusively symptom control and not the pursuit of living longer.

However, no comprehensive data are available on the actual form of treatment in hospices in Germany and the medical care of tumor patients in hospices.

Thus, this study is intended to investigate the care situation of patients with an underlying malignant disease in German hospices, especially with respect to the use of supportive oncological therapies for symptom control.

Methods

Questionnaire and online platform

The research team developed the questionnaire (Fig. 1) with the cooperation of an expert team of hematologists/oncologists, palliative medicine physicians, general practitioners, and palliative-care nurses, as well as the quality circle for palliative medicine of the cooperating specialized outpatient palliative care (SAPV) team. At the same time, the module "tumor-specific therapy in palliative care" of the Hospice and Palliative Survey HOPE was considered for preparing the questionnaire. The formal criteria of the questionnaire were based on the GESIS survey guidelines for written questionnaires, the design of rating scales, and online surveys. Before using the questionnaire, an internal and external evaluation was performed for internal and external consistency and comprehensibility of the individual questions. Therefore, experts from the Leibniz Institute for Social Sciences were consulted for this purpose, and a pretest with subsequent feedback among hospice employees was conducted.

The content of the questions related to (1) structural conditions (location, number of beds, diagnoses, and length of stay); (2) medical care (specialist training and management, visits); and (3) the use of different groups of drugs. The questions were asked as a yes/no question (decision question), an open question, or a single choice question using a six-level Likert-scale. The questionnaire was completed anonymously.
| No. | Questions                                                                 | Answer options                        |
|-----|---------------------------------------------------------------------------|---------------------------------------|
| 1   | How many beds does your hospice have?                                     | (number of beds)                      |
| 2   | What is the size of the city where your hospice is located (by population)?|                                       |
| 3   | Does your hospice have medical management?                                | Yes □ No □                             |
|     |                                                                           | If yes: Which specialism/additional    |
|     |                                                                           | designation does the medical director  |
|     |                                                                           | have: ____________________________     |
| 4   | Which doctors care for your residents?                                    | (e.g., general practitioner, oncologist, etc.) |
|     |                                                                           | ________________________________     |
| 5   | Do at least one of the attending physicians have the additional designation of palliative care? |                                       |
| 6   | How high do you estimate the percentage of your residents who suffer from a malignant disease (e.g., lung cancer, colon cancer, breast cancer, brain tumor, leukemia)? |                                       |
| 7   | How long do your residents with a malignant disease (e.g., lung cancer, colorectal cancer, breast cancer, brain tumor, leukemia) stay in your hospice on average? |                                       |
| 8   | What will end the stay of your hospice residents with a malignant disease (e.g., lung cancer, colon cancer, breast cancer, brain tumor, leukemia)? | 1. Death of a resident  2. Discharge due to the stabilization of the resident  3. Discharge at the resident's own |

**FIG. 1.** Questionnaire.
| 9 | Do your residents with a malignant disease (e.g., lung cancer, colorectal cancer, breast cancer, brain tumor, leukemia) receive one of the following therapies as part of a palliative/symptom-controlling concept if onerous symptoms occur? |
| 1 | Radiotherapy for pain relief? |
| 2 | Radiotherapy to relieve symptoms of bleeding or necrotizing wounds/metastases? |
| 3 | Surgical interventions to alleviate acute symptoms (e.g., pathological or painful fractures, unstable vertebral bodies in metastases, etc.)? |
| 4 | Any of the following drug-based tumor therapies for the alleviation or symptomatic treatment of onerous tumor symptoms (tumor pain, recurrent pleural effusions/ascites)? |
| 5 | Therapies for bone metabolism (e.g., bisphosphonates) to alleviate tumor-related (bone)pain? |
| 6 | Human albumin (protein infusions) in symptomatic protein deficiencies such as pleural effusions, ascites or oedema? |
| 7 | Promoting cell growth through growth factors in anemia, thrombocytopenia or leukopenia? |
| 8 | Erythrocyte concentrates in anemia-related symptoms (e.g., shortness of breath, dizziness, weakness)? |
| 9 | Platelet concentrates for symptoms related to thrombocytopenia (e.g., |
The online platform SoSci Survey, which is freely available for scientific survey projects, was used for the survey. The SoSci platform enables an independent design of the questionnaires. A dynamic design of the questions with different selection types is also possible. We selected either a simple selection option, a dropdown selection, or a multiple selection matrix for this questionnaire. Before the questionnaire was put online, another pretest was conducted through the SoSci platform to test the digital applicability. After the final release, a link to the questionnaire (password-protected) was generated through the platform. After completing the survey, the results were generated automatically in an Excel spreadsheet.

**Hospices interviewed**

From February 5 to 14 of 2019, all hospices in Germany (at that time, \( n = 202 \)) were offered the opportunity to participate in an anonymous online survey concerning the medical and medicinal care of tumor patients in hospices. To increase the willingness to participate, each individual hospice was invited to take part.

---

### Questionnaire Questions

| Number | Question                                                                 |
|--------|--------------------------------------------------------------------------|
| 10     | Are drug therapies continued after admission of residents to your hospice and in the case of corresponding pre-existing illness (e.g., diabetes mellitus, coronary heart disease, renal insufficiency, etc.) for: |
| 11     | In general, how often do your residents with a malignant disease (e.g., lung cancer, colon cancer, breast cancer, brain tumor, leukemia) have medical visits? |
| 12     | How often do medical visits to your residents with a malignant disease (e.g., lung cancer, colon cancer, breast cancer, brain tumor, leukemia) take place through the medical groups listed below (multiple responses possible)? |
|        | 1. High blood pressure                                                   |
|        | 2. Heart failure                                                         |
|        | 3. Coronary heart disease                                                 |
|        | 4. Diabetes mellitus                                                     |
|        | 5. Renal insufficiency                                                   |
|        | 6. COPD/asthma                                                           |
|        | 7. Neurological disorders, e.g., Parkinson's disease, multiple sclerosis, seizures, ALS |
|        | 8. Blood thinners (e.g., Marcumar, Innohep) for thromboses/embolisms, e.g., deep vein thrombosis, pulmonary embolism |
|        | 9. Antibiotics in the case of infections                                  |
|        | 10. Medicinal pain therapy, e.g., morphine, NSAIDs, etc., for symptomatic pain control? |

**Fig. 1.** (Continued)
personally by telephone. Upon approval, a link with a password to the questionnaire was sent to the respective hospice by e-mail.

To further increase the return of answered questionnaires, reminder e-mails were sent to all participating hospices on March 1 and 29 of 2019 with the request to answer the questionnaire. The questionnaire was accompanied by a short information letter. Reference was made to the high proportion of hospice residents who have cancer. In addition, the aim of the survey was explained, namely, the determination of the role of supportive oncological therapy procedures in the care of hospice residents who have cancer and their medical care in hospices in Germany. The survey period ended on April 26, 2019. Participants were informed about the end of the survey period by e-mail.

Statistical methods
The evaluation was descriptively conducted. A nominal scale, ordinal scale, and open-ended questions were used as formats for encrypting (encoding) the data. The variant multiple regression was used for the formats.

Ethical approval
According to the Munich Ethics Committee, no ethical approval was required for this study.

Results
Number of participants and questionnaire return
Of the n = 202 hospices surveyed, n = 11 (5.4%) did not participate in the survey: 2 hospices were not yet open at the time of the survey, and 9 hospices refused to participate. The link to the questionnaire, along with the password, was sent by e-mail to n = 191 (94.6%) hospices. A total of 112 (55.4%) hospices answered the questionnaire online. All participating hospices answered >70% of the questions, with 105 hospices answering >85% of all questions.

Hospice demographics
Most participating hospices (n = 86; 76.8%) had 8 to 12 bed spaces (Table 1). The responding hospices were distributed fairly homogeneously over cities of varying population sizes (<20,000 to >500,000) (Table 1).

For most participating hospices (n = 105; 93.8%), most residents (81%–100%) suffer from a malignant disease. In most hospices (n = 86; 76.8%), the average length of stay is three to four weeks; only a small minority of hospices (n = 15; 13.4%) have a length of stay of five weeks or longer (Table 1). In all participating hospices (n = 112; 100%), most residents die in the hospice.

Table 1. Care Data and Demographic Data Hospices

| Specialist care hospices, n (%) |   |
|---------------------------------|---|
| Does your hospice have a medical management? |   |
| No | 100 (89.3) |
| Yes | 12 (10.7) |
| Specialization of medical director |   |
| Palliative care | 4 (3.6) |
| Hematology and oncology+palliative medicine | 3 (2.7) |
| Psychiatry | 2 (1.8) |
| Internal medicine+palliative care | 1 (0.9) |
| Anesthesia+palliative care | 1 (0.9) |
| General medicine+palliative care | 1 (0.9) |
| Which doctors care for your residents? (Multiple entries possible) |   |
| Palliative medicine |   |
| Family doctor/practitioner/general medicine | 65 (58) |
| Additional specialties if required | 23 (20.5) |
| Oncology | 17 (15.2) |
| Internal medicine | 6 (5.4) |
| Pain medicine | 5 (4.5) |
| Urology | 5 (4.5) |
| Anesthesia | 3 (2.7) |
| Dermatology | 2 (1.8) |
| Dentistry | 2 (1.8) |
| Psychiatry | 2 (1.8) |
| Gynecology | 1 (0.9) |
| Nephrology | 1 (0.9) |
| Neurology | 1 (0.9) |
| Physicians with specified additional designation palliative medicine |   |
| Palliative medicine | 65 (58) |
| SAPV (specialized outpatient palliative care) | 24 (21.4) |
| Anesthesia and palliative care | 5 (4.5) |
| Does at least one of the attending physicians have the additional designation palliative care? |   |
| Yes | 112 (100) |
| No | 0 (0) |

| Medical care hospices, n (%) |   |
|-----------------------------|---|
| How often do your residents with a malignant disease generally have medical visits? |   |
| Daily | 30 (26.8) |
| Weekly | 81 (72.3) |
| Every two weeks | 1 (0.9) |
| How often do your residents with a malignant disease generally have medical visits by the physician groups listed below? |   |
| Family doctor |   |
| Daily | 6 (5.4) |
| Weekly | 62 (55.4) |
| Every two weeks | 2 (1.8) |
| Every three weeks | 3 (2.7) |
| Monthly | 4 (3.6) |
| Never | 32 (28.6) |
| Not specified | 3 (2.7) |
| Hematologist/oncologist |   |
| Weekly | 10 (8.9) |
| Every two weeks | 3 (2.7) |
| Monthly | 2 (1.8) |
| Never | 91 (81.3) |
| Not specified | 6 (5.4) |
| SAPV (specialized outpatient palliative care) |   |
| Daily | 20 (17.9) |
| Weekly | 54 (48.2) |
| Every two weeks | 2 (1.8) |
| Never | 28 (25) |
| Not specified | 8 (7.1) |
| Other specialties on demand | 30 (26.8) |

(continued)
from the hospice due to stabilization of the patients or at the request of relatives/the patients themselves are relatively rare overall (Table 1). Other reasons for terminating the hospice stay are rare overall, with a lack of funds \((n=4; 3.6\%)\) being the most frequently mentioned (Table 1).

**Medical care for hospice residents**

Twelve hospices (10.7%) have a medical director, which, in most cases \((n=10; 8.9\%)\), has attended further education for palliative medicine. Medical hospice direction by hematologists/oncologists is rare \((n=3; 2.7\%)\) (Table 1). All participating hospices \((n=112; 100\%)\) generally provide palliative care-oriented medical care (Table 1). Hospice residents are most often treated by general practitioners and/or palliative medicine physicians \((n=65; 58\%)\) in each case. Care provided by oncologists \((n=17; 15.2\%)\) or an SAPV team \((n=24; 21.4\%)\) takes place rather less frequently (Table 1). In 23 hospices (20.5%), additional disciplines, such as urology, dentistry, or neurology, are consulted as required (Table 1).

Medical visits are predominantly made on a weekly basis \((n=81; 72.3\%)\) to patients with an underlying malignant disease in the participating hospices. In most hospices \((n=91; 81.3\%)\), no visits are made by a hematologist/oncologist. In only 15 (13.4%) hospices do hematologist/oncologists visit tumor patients; in 10 (8.9%) hospices these visits occur weekly (Table 1).

**Supportive oncological therapies**

Radiotherapy and surgical interventions to alleviate symptoms are never or only very rarely used in most surveyed hospices. If used, the indication for radiotherapy focuses on pain relief more than bleeding or necrotizing wounds (Table 2).

Systemic antiproliferative tumor therapies (intravenous chemotherapy, oral tumor therapy, antihormonal therapy, and antibody therapy) to alleviate symptoms are rarely or never used in most hospices surveyed. However, in a small but relevant proportion of participating hospices \((1.8\%–11.6\%)\) these therapies are used under the special indication of “alleviation of symptoms” (Table 2).

Systemic nonantiproliferative tumor therapies (bisphosphonates, human albumin, and growth factors) to alleviate symptoms are used in the hospices surveyed, for the most part, rarely or never. An exception is the use of bisphosphonates for pain relief in skeletal metastases, which are used relatively frequently (Table 2).

Blood products (erythrocyte concentrates, platelet concentrates) for reducing tumor-related symptoms are also used very rarely, or not at all, in most hospices. However, there is also a small group of hospices, where blood products (particularly erythrocyte concentrates) are regularly used for symptom control (Table 2).
The most common supportive oncological tumor therapy for treating tumor-related symptoms in hospices is pain therapy, which is used in almost all responding hospices ($n = 109; 97.3\%$) (Table 2).

### Continuation of a (nononcological) drug therapy

In most hospices (Table 3), medications for treating common nononcological concomitant diseases (such as high blood pressure, heart failure, coronary heart disease, diabetes mellitus, renal insufficiency, lung diseases (chronic obstructive pulmonary disease [COPD], asthma), neurological diseases, thromboses/embolisms, and infections) are continued regularly and frequently. However, antibiotics for treating infections and blood thinners for thromboses/embolisms tend to be used less often.

### Prescription of supportive oncological therapies depending on the medical specialty

The prescription of supportive oncological tumor therapies for symptom control in hospices is performed more frequently in percentage terms by specialists in hematology and oncology. This applies to both antiproliferative and nonantiproliferative medications. In this context, oral medication (antihormonal therapy and oral tumor therapy) predominates in the case of antiproliferative therapies, and the use of bisphosphonates predominates in the case of nonantiproliferative therapies. This trend continues among nononcology specialists for whom antihormonal therapies, in addition to bisphosphonates, are in the foreground (Tables 4 and 5).

### Discussion

The care of tumor patients in hospices still represents an area of tension in the field of palliative medicine. However, tumor-specific therapies aimed at life extension in the last phase of life are regarded as a burden, and their termination is demanded. On the other hand, selected therapies can significantly alleviate symptoms in certain patients. With the increasing number of hospices in Germany, the proportion of patients suffering from malignant disease and spending their last stage of life in hospice increases accordingly. Currently, about 26,800 tumor patients spend the last phase of their lives in inpatient hospices. This study investigated the medical care of these patients.

### Table 2. Use of Supportive Oncological Tumor Therapies for Symptom Relief

|                                      | Never, n (%) | Very rare, n (%) | Rare, n (%) | Sometimes, n (%) | Often, n (%) | Quite often, n (%) | Not selected, n (%) | Total, N (%) |
|--------------------------------------|--------------|------------------|------------|------------------|--------------|-------------------|-------------------|--------------|
| Medical pain therapy                 | 0 (0)        | 0 (0)            | 0 (0)      | 0 (0)            | 0 (0)        | 109 (97.3)        | 3 (2.7)          | 112 (100)    |
| Bisphosphonates                      | 48 (42.9)    | 36 (32.1)        | 12 (10.7)  | 10 (8.9)         | 1 (0.9)      | 0 (0)             | 5 (4.5)          | 112 (100)    |
| Erythrocyte concentrates             | 16 (14.3)    | 60 (53.6)        | 15 (13.4)  | 13 (11.6)        | 2 (1.8)      | 0 (0)             | 6 (5.4)          | 112 (100)    |
| Antihormonal therapy                | 21 (18.8)    | 66 (58.9)        | 12 (10.7)  | 8 (7.1)          | 0 (0)        | 0 (0)             | 5 (4.5)          | 112 (100)    |
| Radiotherapy for pain relief         | 49 (43.8)    | 36 (32.1)        | 12 (10.7)  | 12 (10.7)        | 0 (0)        | 0 (0)             | 3 (2.7)          | 112 (100)    |
| Surgical intervention               | 46 (41.1)    | 51 (45.5)        | 8 (7.1)    | 4 (3.6)          | 0 (0)        | 0 (0)             | 3 (2.7)          | 112 (100)    |
| Antibody therapy                    | 52 (46.4)    | 43 (38.4)        | 10 (8.9)   | 2 (1.8)          | 0 (0)        | 0 (0)             | 5 (4.5)          | 112 (100)    |
| Human albumin                       | 66 (58.9)    | 28 (25)          | 9 (8)      | 4 (3.6)          | 0 (0)        | 0 (0)             | 5 (4.5)          | 112 (100)    |
| Platelet concentrates               | 68 (60.7)    | 30 (26.8)        | 6 (5.4)    | 2 (1.8)          | 0 (0)        | 0 (0)             | 6 (5.4)          | 112 (100)    |
| Intravenous chemotherapy             | 71 (63.4)    | 28 (25)          | 4 (3.6)    | 6 (5.4)          | 0 (0)        | 0 (0)             | 3 (2.7)          | 112 (100)    |
| Radiotherapy for bleeding wounds     | 74 (66.1)    | 26 (23.2)        | 4 (3.6)    | 4 (3.6)          | 0 (0)        | 0 (0)             | 4 (3.6)          | 112 (100)    |
| Growth factors                       | 78 (69.6)    | 24 (21.4)        | 3 (2.7)    | 1 (0.9)          | 0 (0)        | 0 (0)             | 6 (5.4)          | 112 (100)    |

### Table 3. Prescribed Drug Therapy for Nontumor Diseases

|                                      | Never, n (%) | Very rare, n (%) | Rare, n (%) | Sometimes, n (%) | Often, n (%) | Quite often, n (%) | Not selected, n (%) | Total, N (%) |
|--------------------------------------|--------------|------------------|------------|------------------|--------------|-------------------|-------------------|--------------|
| COPD/asthma                          | 0 (0)        | 2 (1.8)          | 1 (0.9)    | 10 (8.9)         | 54 (48.2)    | 42 (37.5)         | 3 (2.7)          | 112 (100)    |
| Neurological diseases                | 1 (0.9)      | 4 (3.6)          | 2 (1.8)    | 15 (13.4)        | 46 (41.1)    | 39 (34.8)         | 5 (4.5)          | 112 (100)    |
| Diabetes mellitus                    | 0 (0)        | 1 (0.9)          | 2 (1.8)    | 24 (21.4)        | 46 (41.1)    | 35 (31.3)         | 4 (3.6)          | 112 (100)    |
| Hypertension                         | 1 (0.9)      | 5 (4.5)          | 4 (3.6)    | 35 (31.3)        | 48 (42.9)    | 16 (14.3)         | 3 (2.7)          | 112 (100)    |
| Heart failure                        | 2 (1.8)      | 6 (5.4)          | 4 (3.6)    | 42 (37.5)        | 42 (37.5)    | 13 (11.6)         | 3 (2.7)          | 112 (100)    |
| Renal failure                        | 2 (1.8)      | 6 (5.4)          | 12 (10.7)  | 36 (32.1)        | 41 (36.6)    | 12 (10.7)         | 3 (2.7)          | 112 (100)    |
| Coronary heart disease               | 1 (0.9)      | 5 (4.5)          | 8 (7.1)    | 43 (38.4)        | 39 (34.8)    | 13 (11.6)         | 3 (2.7)          | 112 (100)    |
| Anticoagulation                      | 1 (0.9)      | 17 (15.2)        | 14 (12.5)  | 45 (40.2)        | 27 (24.1)    | 5 (4.5)           | 3 (2.7)          | 112 (100)    |
| Antibiotics                          | 0 (0)        | 11 (9.8)         | 14 (12.5)  | 60 (53.6)        | 15 (13.4)    | 9 (8)             | 3 (2.7)          | 112 (100)    |
Table 4. Percentage of the Prescribing Specialist Group (Hospices with Oncologists/Hospices with Nononcologists) in Relation to the Prescription of Antiproliferative Substances

| Therapy                  | Frequency of use | Nononcologists (N = 95), % (n) | Oncologists (N = 17), % (n) | Total (N = 112), % (n) |
|--------------------------|------------------|---------------------------------|-----------------------------|------------------------|
| **Oral tumor therapy**   |                  |                                 |                             |                        |
| Never                    | 20 (19)          | 11.8 (2)                        | 18.8 (21)                   |                        |
| Very rare                | 60 (57)          | 52.9 (9)                        | 58.9 (66)                   |                        |
| Rare                     | 10.5 (10)        | 11.8 (2)                        | 10.7 (12)                   |                        |
| Sometimes                | 5.3 (5)          | 17.7 (3)                        | 7.1 (8)                     |                        |
| Often                    | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 4.2 (4)          | 5.9 (1)                         | 4.5 (5)                     |                        |
| **Antihormonal therapy**|                  |                                 |                             |                        |
| Never                    | 13.7 (13)        | 17.7 (3)                        | 14.3 (16)                   |                        |
| Very rare                | 57.9 (55)        | 29.4 (5)                        | 53.6 (60)                   |                        |
| Rare                     | 10.5 (10)        | 29.4 (5)                        | 13.4 (15)                   |                        |
| Sometimes                | 11.6 (11)        | 11.8 (2)                        | 11.6 (13)                   |                        |
| Often                    | 1.1 (1)          | 5.9 (1)                         | 1.8 (2)                     |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 5.3 (5)          | 5.9 (1)                         | 5.4 (6)                     |                        |
| **Antibodies**           |                  |                                 |                             |                        |
| Never                    | 47.4 (45)        | 41.2 (7)                        | 46.4 (52)                   |                        |
| Very rare                | 41.1 (39)        | 23.5 (4)                        | 38.4 (43)                   |                        |
| Rare                     | 7.4 (7)          | 17.7 (3)                        | 8.9 (10)                    |                        |
| Sometimes                | 0.0 (0)          | 11.8 (2)                        | 1.8 (2)                     |                        |
| Often                    | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 4.2 (4)          | 5.9 (1)                         | 4.5 (5)                     |                        |
| **Intravenous chemotherapy** |          |                                 |                             |                        |
| Never                    | 67.4 (64)        | 41.2 (7)                        | 63.4 (71)                   |                        |
| Very rare                | 23.2 (22)        | 35.3 (6)                        | 25 (28)                     |                        |
| Rare                     | 3.2 (3)          | 5.9 (1)                         | 3.6 (4)                     |                        |
| Sometimes                | 4.2 (4)          | 11.8 (2)                        | 5.4 (6)                     |                        |
| Often                    | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 2.1 (2)          | 5.9 (1)                         | 2.7 (3)                     |                        |

Table 5. Percentage of the Prescribing Specialist Group (Hospices with Oncologists/Hospices with Nononcologists) in Relation to the Prescription of Blood Products, Bisphosphonates, and Human Albumin

| Therapy                  | Frequency of use | Nononcologists (N = 95), % (n) | Oncologists (N = 17), % (n) | Total (N = 112), % (n) |
|--------------------------|------------------|---------------------------------|-----------------------------|------------------------|
| **Bisphosphonates**      |                  |                                 |                             |                        |
| Never                    | 17.9 (17)        | 11.8 (2)                        | 17 (19)                     |                        |
| Very rare                | 34.7 (33)        | 23.5 (4)                        | 33.1 (37)                   |                        |
| Rare                     | 21.1 (20)        | 11.8 (2)                        | 19.6 (22)                   |                        |
| Sometimes                | 14.7 (14)        | 41.2 (7)                        | 18.8 (21)                   |                        |
| Often                    | 6.3 (6)          | 5.9 (1)                         | 6.3 (7)                     |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 5.3 (5)          | 5.9 (1)                         | 5.4 (6)                     |                        |
| **Human albumin**        |                  |                                 |                             |                        |
| Never                    | 62.1 (59)        | 41.2 (7)                        | 58.9 (66)                   |                        |
| Very rare                | 25.3 (24)        | 23.5 (4)                        | 25 (28)                     |                        |
| Rare                     | 7.4 (7)          | 11.8 (2)                        | 8 (9)                       |                        |
| Sometimes                | 1.1 (1)          | 17.7 (3)                        | 3.6 (4)                     |                        |
| Often                    | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 4.2 (4)          | 5.9 (1)                         | 4.5 (5)                     |                        |
| **Erythrocyte concentrates** |             |                                 |                             |                        |
| Never                    | 45.3 (43)        | 29.4 (5)                        | 42.9 (48)                   |                        |
| Very rare                | 33.7 (32)        | 23.5 (4)                        | 32.1 (36)                   |                        |
| Rare                     | 9.5 (9)          | 17.7 (3)                        | 10.7 (12)                   |                        |
| Sometimes                | 7.4 (7)          | 17.7 (3)                        | 8.9 (10)                    |                        |
| Often                    | 0 (0)            | 5.9 (1)                         | 0.9 (1)                     |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 4.2 (4)          | 5.9 (1)                         | 4.5 (5)                     |                        |
| **Platelet concentrates**|                  |                                 |                             |                        |
| Never                    | 63.2 (60)        | 47.1 (8)                        | 60.7 (68)                   |                        |
| Very rare                | 26.3 (25)        | 29.4 (5)                        | 26.8 (30)                   |                        |
| Rare                     | 4.2 (4)          | 11.8 (2)                        | 5.4 (6)                     |                        |
| Sometimes                | 1.1 (1)          | 5.9 (1)                         | 1.8 (2)                     |                        |
| Often                    | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Quite often              | 0 (0)            | 0 (0)                           | 0 (0)                       |                        |
| Not selected             | 5.3 (5)          | 5.9 (1)                         | 5.4 (6)                     |                        |
bed capacities (Table 1), and (3) the response rate was 55% (participation of 112 out of 202 requested hospices), thus meaningful generalizable data were generated.32–34

Most hospices in Germany are supervised by general practitioners with or without additional training in the field of palliative medicine. In a smaller proportion, consultants from various disciplines and/or an SAPV team are involved. At this time, hematologists/oncologists are rarely represented. In principle, a palliative medical care option is ensured for all hospices (Table 1). These data are consistent with other surveys concerning medical hospice care.21

As in palliative care more generally,4 most hospice residents suffer from malignant diseases (Table 1). In most of the hospices surveyed, the patient’s stay is three to four weeks, however, a smaller proportion of the residents seem to remain in the hospice for several weeks to months (Table 1). Especially for this patient group with an even longer lifetime, the question arises in the literature concerning the use of a supportive oncological therapy to alleviate symptoms.3 For these therapies, feasibility and practicability in hospices3,7 and a positive influence on the quality of life of palliative patients has been demonstrated12–14,35

Our study confirmed the use of supportive oncological therapies in inpatient hospices. But the future challenge will be the identification of suitable patients in hospices. Further investigations are certainly required.3

However, the results of the current survey provide indications that supportive oncological therapies are used only in a small minority of hospices in Germany or are only rarely included in the therapy of severely ill patients with underlying malignant disease (Table 2). Since the proportion of tumor patients in the hospices is comparable, this could either be due to a lack of fundamental consensus on the use of supportive oncological therapies in hospices10,12,20,30,31 and/or to a lack of care: On the one hand, only a small proportion of hospices are co-supported by a hematologist/oncologist (Table 1) and, on the other hand, the use of supportive oncological tumor therapies in tumor patients in hospices seems to be influenced by the co-supervision by a hematologist/oncologist; in hospices with hematologists/oncologists, these therapies were used more frequently in percentage terms than in hospices without hematologists/oncologists (Tables 4 and 5).3

This could be partly due to the fact that general practitioners—who are responsible for most of the medical care in hospices (Table 1)—usually prefer the use of tumor-specific therapies to be performed by their respective specialists.36 This is also supported by the fact that, of the supportive oncological tumor therapies, bisphosphonates—which may not be associated with the special tumor therapeutics in the view of the prescribing physicians—are most frequently prescribed by nononcologists for treating tumor-related bone pain.

In contrast to supportive oncological therapies, existing medications for chronic diseases, such as COPD, heart failure, or diabetes mellitus, are often continued in hospices (Table 3). The continued use of such chronic medication in palliative medicine and especially in hospices is controversially discussed.37,38

In the case of diabetes mellitus, an elevated blood sugar is often tolerated to avoid hypoglycemia, and the recommendations of the specialist society are more in favor of a reduction of the antidiabetics.39 For treating the symptoms of fatigue, which is frequently described especially in cardiological and pneumological patients40,41 opiates are often used before other medications.31,42 Especially toward the end of life, the symptoms of fatigue, lack of appetite, and weakness also come to the fore in nononcological diseases.42 The continued use of chronic medication in inpatient hospices will certainly have to be discussed critically with regard to whether they should be continued when their benefits are typically realized only after years.

Overall, the use of nononcological (chronic) medication and supportive oncological tumor therapy in hospices seems to be influenced by the medical discipline in charge. Another limiting factor could be structural conditions, such as those required for special supportive oncological therapies (e.g., radiotherapies or transfusion of blood products).3

Taking into account the increasing establishment of day hospices in Germany33,44 and the variable lifetime of hospice residents, the use of supportive oncological therapy options in the hospice sector should always be carefully examined to achieve the best possible symptom control and thus the best possible quality of life for patients.

Limitations
There is only information available from just over half of German hospices. However, this response rate is considered sufficient, especially in online surveys, to make valid statements.32–34 With regard to subject-specific care, especially the number of supervising hematologists/oncologists [n = 17 (15.2%) in all participating hospices] may be underestimated, as
increasing SAPV care may involve hematology/oncology-trained SAPV physicians in the care of hospice patients. In addition, the care provided by palliative-care physicians, as indicated by the hospices, does not allow conclusions to be drawn about the basic specialism of the corresponding physicians, limiting statements about specialist medical care. It was not possible to identify the representative from each hospice who answered the survey without fail. Therefore, different perspectives from individual disciplines (nurses, physicians, administrators, etc.), which may have influence on the response behavior, cannot be excluded.

Conclusions
General practitioners with or without additional palliative medicine qualifications usually provide care for patients with an underlying malignant disease in hospices. Co-treatment by a hematologist/oncologist is rare but is nevertheless practiced in a small minority of hospices. In contrast to nononcological medications, supportive oncological therapies are never or rarely used. However, if a hematologist/oncologist also supervises a hospice, supportive oncological therapies are more frequent in percentage terms.

At this time of care, it is reasonable to assume that hematology/oncology and palliative medicine are only occasionally practiced as a common care concept in the sense of holistic care of tumor patients in hospices in Germany. As already implemented in some hospices, hospice care and the administration of supportive oncological therapies for improved symptom control can be a common and feasible care concept for tumor patients in the last stage of their disease.

There are, of course, a variety of open questions/obstacles to increased use, such as assumption of costs, training of physicians, optimal patient selection and overall assessment of the benefits versus burdens of supportive oncological interventions.

Authors’ Contributions
Conceptualization and writing—original draft by U.K. Methodology and writing—original draft by U.V.-K. Project administration and formal analysis by A.H. Conceptualization, methodology, formal analysis, and writing—reviewing and editing by F.K.

Funding Information
No funding was received.

Author Disclosure Statement
U.K., U.V.-K., and A.H. have no conflict of interests. F.K. indicates consulting activities for Servier, Elsevier, Astellas, GSK, MSD, and Novartis.

References
1. DHPV. Facts, figures and data on hospice and palliative work (DHPV, Zahlen, Daten und Fakten zur Hospiz- und Palliativarbeit); 2022. Available from: https://www.dhpv.de/zahlen_daten_fakten.html [Last accessed: January 6, 2022].
2. Jansky M, Nauck F, Jaspers B. Expert opinion on the need of hospice beds in North Rhine-Westphalia (Gutachten zum Bedarf an Hospizbetten in Nordrhein-Westfalen); 2017. Available from: https://alpha-nrw.de/wp-content/uploads/2017/05/gutachten_bedarf_hospizbetten nrw_2017.pdf [Last accessed: January 6, 2022].
3. Kaiser U, Vehling-Kaiser U, Kück F, et al. Use of symptom-focused oncological cancer therapies in hospices: A retrospective analysis. BMC Palliat Care 2020;19(1):40; doi: 10.1186/s12904-020-00648-4.
4. Dasch B, Blum K, Vogelsang H, et al. Epidemiological study on place of death for cancer patients (Epidemiologische Untersuchung zum Sterbeort von Tumorpatienten). Dtsch Med Wochenschr 2016;141(17):e158–e165; doi: 10.1055/s-0042-111296.
5. Dasch B, Lenz P. The places of death of cancer patients over time (Der Sterbeort von Tumorpatienten im zeitlichen Trend). Der Onkologe 2021; 27(6):602–609; doi: 10.1007/s00761-021-00926-7.
6. Schonwetter RS, Roscoe LA, Nwosu M, et al. Quality of life and symptom control in hospice patients with cancer receiving chemotherapy. J Palliat Med 2006;9(3):638–645; doi: 10.1089/jpm.2006.9.638.
7. Schonwetter RS, Roscoe LA, Nwosu M, et al. Quality of life and symptom control in hospice patients with cancer receiving chemotherapy. J Palliat Med 2006;9(3):638–645; doi: 10.1089/jpm.2006.9.638.
8. Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncol 2015;16(5):509–521; doi: 10.1016/S1470-2045(15)70113-0.
9. Prigerson HG, Yao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 2015;1(6):778–784; doi: 10.1001/jamaoncol.2015.2378.
10. LeBlanc TW, Egan PC, Olaszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood 2018; 132(7):717–726; doi: 10.1182/blood-2018-03-842575.
11. Orrer J, Still D, Day R, et al. The experiences of patients undergoing blood transfusion in a day hospice. Int J Palliat Nurs 2013;19(4):171–176; doi: 10.12968/ijn.2013.19.4.171.
12. Park KR, Lee CG, Tseng YD, et al. Palliative radiation therapy in the last 30 days of life: A systematic review. Radiother Oncol 2017;125(2):193–199; doi: 10.1016/j.radonc.2017.09.016.
13. Barthelemey N, Jansen N, Gennings C, et al. [Does radiotherapy have a role in end-of-life care?]. Rev Med Liege 2012;67(3):128–132.
14. van Oorschot B, Schuler M, Simon A, et al. Patterns of care and course of symptoms in palliative radiotherapy: A multicenter pilot study analysis. Strahlenther Onkol 2011;187(8):461–466; doi: 10.1007/s00066-011-2231-9.
15. Haverhals LM, Manheim CE, Mor V, et al. The experience of providing hospice care concurrent with cancer treatment in the VA. Support Care Cancer 2019;27(4):1263–1270; doi: 10.1007/s00520-018-4552-2.
16. Mor V, Wagner TH, Levy C, et al. Association of expanded VA hospice care with aggressive care and cost for veterans with advanced lung cancer. JAMA Oncol 2019;5(6):810–816; doi: 10.1001/jamaoncol.2019.0081.
17. Hui D, Strube H. Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol 2016;13(3):159–171; doi: 10.1038/nrclinonc.2015.201.
18. Howie L, Peppercorn J. Early palliative care in cancer treatment: Rationale, evidence and clinical implications. Ther Adv Med Oncol 2013;5(6):318–323; doi: 10.1177/1758834013500375.
19. Mor V, Joyce NR, Coté DL, et al. The rise of concurrent care for veterans with advanced cancer at the end of life. Cancer 2016;121(5):782–790; doi: 10.1002/cncr.29827.
20. Alt-Epping B, Pache S, Lindena G, et al. Tumor-specific therapies in palliative care (Tumorspezifische Therapien in der Palliativmedizin). Zeitschrift für Palliativmedizin 2008;9(03):E0, 026.

21. Weber M, Kuhlenbäumer M, Mutschler B, et al. Medical Inpatients HospiceCare Experiences and Preferences of Family Doctors (Ärztliche Patienten-betreuung im stationären Hospiz Hausärztliche Erfahrungen und Präferenzen). Z Allg Med 2004;80(10):425–430; doi: 10.1055/s-2004-820386.

22. MDS. Specialized outpatient palliative care (SAPV) and inpatient hospice care (Spezialisierte ambulante Palliativversorgung (SAPV) und stationäre Hospizversorgung); 2019. Available from: https://www.aok.de/gp/fileadmin/user_upload/Pflege/Hospiz_und_Palliativmedizin/Stationaere_Hospize/BGA_SAPV_und_stationaere_Hospizversorgung.pdf [Last accessed: April 26, 2022].

23. HOPE Module Tumor-specific therapies in palliative care (HOPE Modul Tumorspezifische Therapien in der Palliativmedizin). 2007. Available from: https://www.dgpalliativmedizin.de/images/stories/pdf/doku/AG%20Forschung%202007%20HOPE%20%20Tumortherapie.pdf [Last accessed: February 5, 2022].

24. Lenzner T, Menold N. GESIS survey guidelines question wording. Leibniz-Institut für Sozialwissenschaften 2016;2; doi: 10.15465/gesis-sg_en_017.

25. Menold N, Bogner K. GESIS survey guidelines design of rating scales in questionnaire. Leibniz-Institut für Sozialwissenschaften 2016;2; doi: 10.15465/gesis-sg_en_015.

26. Bandilla W. GESIS survey guidelines Web surveys. Leibniz-Institut für Sozialwissenschaften 2016;2; doi: 10.15465/gesis-sg_en_003.

27. Lenzner T, Neupert C, Otto W. GESIS survey guidelines cognitive pretesting. Leibniz-Institut für Sozialwissenschaften 2016;2; doi: 10.15465/gesis-sg_en_010.

28. Shih T-H, Fan X. Comparing response rates from web and mail surveys: A meta-analysis. Field Methods 2008;20(3):249–271; doi: 10.1177/1525822X08317085.

29. Menold N. GESIS survey guidelines Postal surveys. Leibniz-Institut für Sozialwissenschaften 2016;2; doi: 10.15465/gesis-sg_en_018.

30. van Oorschot B. End-stage cancer: over-commitment to end-of-life care (Krebs im Endstadium: Überengagierte Versorgung am Lebensende). Dtsch Arztebl Int 2018;115(47):17–16; doi: 10.3238/PersOnko.2018214.

31. Tsukamoto H, Itō Y, Kanazawa R, et al. Benefit of palliative chemotherapy and hospice enrollment in late-stage ovarian cancer patients. J Obstet Gynaecol Res 2014;40(5):1399–1406; doi: 10.1111/jog.12320.

32. Cho YI, Johnson TP, VanGeest JB. Enhancing surveys of health care professionals: A meta-analysis of techniques to improve response. Eval Health Prof 2013;36(3):382–407; doi: 10.1177/0163278713496425.

33. Dykema J, Jones NR, Piche T, et al. Surveying clinicians by web: Current practices and recommendations. J Pain Symptom Manage 2018;55(2):508–521.e503; doi: 10.1016/j.jpainsymman.2017.06.010.

34. Cook DA, Wittich CM, Daniels WL, et al. Incentive and reminder strategies to improve response rate for internet-based physician surveys: A randomized experiment. J Med Internet Res 2016;18(9):e244; doi: 10.2196/jmir.6318.

35. Goksu SS, Gunduz S, Unal D, et al. Use of blood transfusion at the end of life: Does it have any effects on survival of cancer patients? Asian Pac J Cancer Prev 2014;15(10):4251–4254; doi: 10.7314/apjcp.2014.15.10.4251.

36. Kaiser U, Vehling-Kaiser U, Hoffmann A, and Kaiser F (2022) Inpatient hospices in Germany: medical care situation and use of supportive oncological therapies for symptom control in tumor patients, Palliative Medicine Reports 3:1, 169–180. DOI: 10.1089/pmr.2022.0026.

37. Janssen K, Haugen DF, Pont L, et al. Safety and effectiveness of palliative drug treatment in the last days of life—A systematic literature review. J Pain Symptom Manage 2018;55(2):508–521.e503; doi: 10.1016/j.jpainsymman.2017.06.010.

38. Quaglietti SE, Atwood JE, Ackerman L, et al. Management of the patient with congestive heart failure using outpatient, home, and palliative care. Prog Cardiovasc Dis 2000;43(3):259–274; doi: 10.1016/s0033-0620(00)19803-3.

39. Lee SJ, Jacobson MA, Johnston CB. Improving diabetes care for hospice patients. Am J Hosp Palliat Care 2016;33(6):517–519; doi: 10.1097/01.FRP.000045578386.

40. Wyscham NG, Cox CE, Wolf SP, et al. Symptom burden of chronic lung disease compared with lung cancer at time of referral for palliative care consultation. Ann Am Thorac Soc 2015;12(9):1294–1301; doi: 10.1513/AnnalsATS.201503-1800C.